Early postpartum abnormal glucose metabolism subtype differs according to mid-trimester lipid profile in women with gestational diabetes mellitus

Fenghua Lai†, Zeting Li†, Shufan Yue†, Ling Pei†, Huangmeng Xiao†, Zhuyu Li**, Yanbing Li†, Haipeng Xiao† and Xiaopei Cao†*

Abstract

Background: It is unknown whether early postpartum abnormal glucose metabolism (AGM) in women with previous gestational diabetes mellitus (GDM) is related to their mid-trimester lipid profile. The aim of this study was to characterize the mid-trimester lipid profile of women who experienced GDM and developed into different pathophysiologic subtypes of early postpartum AGM.

Methods: A retrospective cohort study of 498 women with history of GDM was conducted. A 75-g oral glucose tolerance test (OGTT) and plasma lipid measurements were performed at 24–28 weeks of gestation and 6–12 weeks of postpartum. Insulin secretion and sensitivity were estimated using early postpartum OGTT-based indices.

Results: Women in the mid-trimester dyslipidemia group had higher postpartum 30-min and 2-h plasma glucose, higher postpartum 2-h plasma insulin, higher postpartum triglyceride (TG), higher postpartum low density lipoprotein cholesterol (LDL-c) concentrations, lower postpartum 30-min insulinogenic index (IGI₃₀), lower postpartum insulin sensitivity index (ISI), and lower postpartum disposition index than those in the normal lipid group (all \( P < 0.05 \)). Abnormal mid-trimester TG and LDL-c concentrations were associated with postpartum AGM (adjusted odds ratio [OR] = 1.786, 95 % confidence interval [CI] = 1.142–2.425; and adjusted OR = 1.621, 95 % CI = 1.323–2.051, respectively; both \( P < 0.05 \)). AGM women with low IGI₃₀ and low ISI had higher mid-trimester total cholesterol and LDL-c concentrations, and AGM women with low ISI had higher mid-trimester TG concentrations than women with NGT or other subtypes of AGM (all \( P < 0.05 \)).

Conclusions: GDM women with abnormal mid-trimester TG and LDL-c were predisposed to early postpartum AGM. Postpartum AGM women who experienced GDM had heterogeneous mid-trimester lipid profile when classified according to their pathophysiologic subtype.

Keywords: Gestational diabetes mellitus, Lipid profile, Mid-trimester, Glucose metabolism, Postpartum

* Correspondence: caoxp@mail.sysu.edu.cn
† Fenghua Lai and Zeting Li contributed equally to this work and should be considered as co-first authors.
*Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Rd, 510080 Guangzhou, China
Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Gestational diabetes mellitus (GDM) is a common complication of pregnancy that affects approximately 18% of pregnancies per year worldwide [1]. Insulin resistance, a main factor in GDM pathophysiology, is associated with a more atherogenic lipid profile. The high-fat diet, weight gain, and increased body mass index are key risk factors of developing GDM [2]. GDM not only increases the risk of GDM in future pregnancies [3], but also increases the risk of postpartum type 2 diabetes mellitus (T2DM) [4]. The American Diabetes Association recommended that a 75-g oral glucose tolerance test (OGTT) should be performed at 4–12 weeks of postpartum in every woman who experienced GDM [5]. However, the rate of attendance was still low [6]. The early diagnosis of postpartum prediabetes can provide an opportunity to reduce the risk of T2DM through interventions comprising appropriate lifestyle modifications. Therefore, the early identification of biomarkers associated with postpartum abnormal glucose metabolism (AGM) should promote health and help prevent subsequent T2DM.

Pregnancy substantially alters lipid metabolism. Previous studies showed that pregnancies with GDM were characterized by more severe hyperlipidemia than pregnancies with normal glucose tolerance (NGT) [7]. Dyslipidemia in pregnancy were associated with pregnancy complications, such as pre-eclampsia, pre-term birth, and postpartum hypertension in the longer term [8, 9]. Furthermore, a previous case-control study demonstrated that GDM pathophysiologic subtype differed in their gestational lipid profiles, which emphasized the pathophysiologic heterogeneity of GDM [10]. However, it is unknown whether early postpartum AGM in women who have experienced GDM differs according to their gestational lipid profile.

Therefore, a retrospective cohort study to explore the relationship between lipid profile during the mid-trimester and postpartum AGM in women who had previously experienced GDM was conducted. Furthermore, the mid-trimester lipid profile of the women was analyzed according to their pathophysiologic subtype of early postpartum AGM.

Methods
Study participants
This was a retrospective cohort study with 652 women who experienced GDM and attended postpartum follow-up clinics at the First Affiliated Hospital, Sun Yat-sen University between January 2015 and December 2018. In total, 110 women for whom plasma insulin concentrations were not assayed in blood samples from the OGTT at 6–12 weeks of postpartum and 44 women for whom plasma lipid concentrations were not measured during 24–28 weeks of gestation were excluded. The remaining 498 women were included in the final analysis (Fig. 1). All the eligible women were categorized into normal lipid group and dyslipidemia group according to their lipid profile at 24–28 weeks of gestation.

Data collection and metabolic measurements
The following maternal data were collected from medical records: age at delivery, first-degree family history of diabetes, and whether insulin therapy was administered during pregnancy. A 75-g OGTT and plasma lipid measurements were performed at 24–28 weeks of gestation and 6–12 weeks of postpartum. Fasting blood samples for the measurement of plasma lipid concentrations were withdrawn from an antecubital vein after an overnight fast of at least 8 h. Between 24 and 28 gestational weeks, fasting plasma glucose (FPG), 1-h plasma glucose (1hPG), and 2-h plasma glucose (2hPG) were performed during a 75-g OGTT. In the early postpartum 75-g OGTT, the levels of plasma glucose and serum insulin were measured at fasting, 30 min and 2 h after the ingestion of the glucose formulation. All blood samples were analyzed in the laboratory of the Department of Biochemistry of the First Affiliated Hospital, Sun Yat-sen University.

Pancreatic β-cell function was estimated using the 30-min insulinogenic index (IGI30), which was calculated using the plasma insulin and glucose concentrations at 0-min and 30-min of the OGTT [11], and homoeostasis model assessment of β-cell function (HOMA-β) [12]. IGI30 was calculated as \( \frac{\text{insulin}_{0\text{min}} - \text{insulin}_{30\text{min}}}{\text{glucose}_{0\text{min}} - \text{glucose}_{30\text{min}}} \) and HOMA-β was calculated as \( 20 \times \frac{\text{insulin}_{0\text{min}} \times \text{glucose}_{0\text{min}}}{\text{insulin}_{0\text{min}} + \text{glucose}_{0\text{min}}} \). Insulin sensitivity was assessed using the composite (Matsuda) insulin sensitivity index (ISI) [13] and the homoeostasis model assessment of insulin resistance (HOMA-IR) index [12]. The composite ISI was calculated using the following formula: \( 10,000 / \sqrt{((\text{fasting glucose} / \text{mg/dL}) \times (\text{fasting insulin} / \mu\text{U/mL}) \times (\text{mean glucose} / \text{mg/dL}) \times (\text{mean insulin} / \mu\text{U/mL}))} \). HOMA-IR was calculated as \( (\text{fasting glucose} / \mu\text{mol/L}) \times (\text{fasting insulin} / \mu\text{U/mL}) / 22.5 \). Disposition index (DI) was estimated by multiplying IGI30 with composite ISI to reflect β-cell function adjusting for the insulin sensitivity [14].

Definitions of GDM, dyslipidemia, and AGM
GDM was diagnosed according to “International Association of Diabetes and Pregnancy Study Groups” criteria [15], when any serum glucose value equaled or exceeded the appropriate threshold values during the OGTT performed between 24 and 28 weeks of gestation: FPG: 5.1 mmol/L; 1hPG: 10.0 mmol/L; and 2hPG: 8.5 mmol/L.

Dyslipidemia during the mid-trimester of pregnancy was defined using the recommended reference values for
maternal serum lipid profiles in China: total cholesterol (TC) ≥ 7.50 mmol/L, triglyceride (TG) ≥ 3.56 mmol/L, high-density lipoprotein cholesterol (HDL-c) ≤ 1.41 mmol/L, and low-density lipoprotein cholesterol (LDL-c) ≥ 4.83 mmol/L [16].

All the women with GDM were advised to undergo another OGTT at 6–12 weeks of postpartum. AGM was diagnosed according to the guidelines of the Chinese Diabetes Society (2017 edition): FPG ≥ 6.1 mmol/L or 2hPG ≥ 7.8 mmol/L (including impaired fasting glucose [IFG], 6.1 mmol/L ≤ FPG < 7.0 mmol/L; impaired glucose tolerance (IGT), 7.8 mmol/L ≤ 2hPG < 11.0 mmol/L; and T2DM, FPG ≥ 7.0 mmol/L or 2hPG ≥ 11.1 mmol/L) [17].

### Statistical analysis
Nonnormally distributed continuous variables were presented as median with interquartile range (IQR), and categorical variables were expressed as number (percentage). The Mann-Whitney U-test for continuous variables and the chi-square test for categorical variables were used to identify differences between normal lipid group and dyslipidemia group. Logistic regression analysis was used to determine whether abnormal TC, TG, HDL-c, and LDL-c concentrations during the middle trimester of pregnancy were independently associated with early postpartum AGM.

The IGI\textsubscript{30} and composite ISI threshold values to categorize the participants with postpartum AGM into two groups were determined, respectively. The cut-off values for IGI\textsubscript{30} and composite ISI were calculated to maximize the Youden Index: max (sensitivity + specificity – 1) [18]. The optimal cut-off for the categorization of IGI\textsubscript{30} into high and low values was 8.72 and that for ISI was 6.98. All the eligible women who had experienced GDM were categorized into five pathophysiologic subtypes, according to their blood glucose concentration, IGI\textsubscript{30} categorization, and ISI categorization at 6–12 weeks of postpartum: NGT, AGM-(low IGI\textsubscript{30} + low ISI), AGM-(low IGI\textsubscript{30} + high ISI), AGM-(high IGI\textsubscript{30} + low ISI), and AGM-(high IGI\textsubscript{30} + high ISI). The Kruskal-Wallis test was used to identify differences among these five groups, and then least-significant difference tests were used for pairwise comparisons between two groups. All the analyses were performed using SPSS 25.0 (IBM Corporation, Armonk, NY, USA). Two-sided \( P \) values of < 0.05 were considered to represent statistical significance.

### Results
#### Baseline characteristics at 24–28 weeks of gestation
On the basis of their lipid profiles at 24–28 weeks of gestation, 117 women with GDM were categorized in the dyslipidemia group and 381 were placed in the normal lipid group. Table 1 showed the comparison of the
demographic and metabolic characteristics of women with GDM at 24–28 weeks of gestation in the two groups. The prevalence of insulin therapy during pregnancy in the mid-trimester dyslipidemia group was higher than that in normal lipid group (2.56 % vs. 1.31 %, P = 0.009). The women in the dyslipidemia group had higher 1hPG (10.00 [9.20–10.75] mmol/L vs. 9.80 [8.80–10.40] mmol/L, P = 0.007), higher 2hPG (9.10 [8.55–9.80] mmol/L vs. 8.80 [8.40–9.40] mmol/L, P = 0.008), higher TG (3.03 [2.14–3.83] mmol/L vs. 2.09 [1.73–2.58] mmol/L, P < 0.001), and higher LDL-c (4.11 [3.81–4.61] mmol/L vs. 3.31 [2.91–3.69] mmol/L, P < 0.001) than the women in the normal lipid group.

### Comparisons of the metabolic characteristics at 6–12 weeks of postpartum
After delivery, the incidences of early postpartum T2DM, IGT, and IFG in the mid-trimester dyslipidemia group were higher than that in the normal lipid group. Women in the mid-trimester dyslipidemia group had higher 30-min plasma glucose, higher 2hPG, and higher 2-h plasma insulin of the postpartum OGTT, higher postpartum TG, and higher postpartum LDL-c than those in the normal lipid group. Compared with women in the mid-trimester normal lipid group, those in the dyslipidemia group had lower IGI30, lower ISI, and lower DI in the early postpartum period (Table 2).

### Relationships between abnormal mid-trimester lipid profile and early postpartum AGM
Logistic regression analyses (Table 3) showed that abnormal mid-trimester TG (crude odds ratio [OR] = 1.961, 95 % confidence interval [CI] = 1.177–2.536, P = 0.009) and abnormal LDL-c (crude OR = 1.579, 95 % CI = 1.274–1.936, P = 0.039) were associated with the presence of early-postpartum AGM. After adjustment for maternal age, insulin therapy, family history of diabetes, and the three OGTT blood glucose values at 24–28 weeks of gestation, and lipid parameters at 6–12 weeks of postpartum, these associations remained significant (mid-trimester abnormal TG: adjusted OR = 1.786, 95 % CI = 1.142–2.425, P = 0.031; and abnormal LDL-c: adjusted OR = 1.621, 95 % CI = 1.323–2.051, P = 0.035). In contrast, no significant associations were found between the abnormal mid-trimester TC or HDL-c and the presence of early postpartum AGM.

### Comparison of mid-trimester lipid profile among women with different early postpartum glucose metabolism subtypes
After delivery, the prevalences of NGT, AGM-(low IGI30 + low ISI), AGM-(low IGI30 + high ISI), AGM-(high IGI30 + low ISI), and AGM-(high IGI30 + high ISI) were 60.64 % (302/498), 8.63 % (43/498), 13.05 % (65/498), 12.25 % (61/498), and 5.42 % (27/498). Compared with women with NGT or other subtypes of AGM, those with AGM-(low IGI30 + low ISI) women had higher mid-trimester TC and LDL-c concentrations (both P < 0.05) (Fig. 2a, d). Women with AGM-(low IGI30 + low ISI) or AGM-(high IGI30 + low ISI) had higher mid-trimester TG concentrations than women with NGT, AGM-(low IGI30 + high ISI), or AGM-(high IGI30 + high ISI) (P < 0.05) (Fig. 2b). No significant differences were found in mid-trimester HDL-c concentrations among the women with postpartum NGT or one of the four subtypes of AGM (Fig. 2c).

### Discussion
In the present study, the incidence of early postpartum AGM in GDM women with mid-trimester dyslipidemia was significantly higher than that with normal lipid during midterm pregnancy. In particular, GDM women with abnormal mid-trimester TG and LDL-c concentrations were predisposed to early postpartum AGM. An elevated mid-trimester TG concentration was associated with low insulin sensitivity in postpartum women with AGM who

---

**Table 1** Demographic and metabolic characteristics of GDM women at 24–28 gestational weeks between midtrimester dyslipidemia group and normal lipid group

| Variables                      | Dyslipidemia group (n = 117) | Normal lipid group (n = 381) | P value |
|--------------------------------|-----------------------------|-----------------------------|---------|
| Age (years)                    | 34 (31–37)                  | 34 (31–37)                  | 0.543   |
| Family history of diabetes     | 27 (23.08 %)                | 85 (22.31 %)                | 0.862   |
| Prevalence of insulin therapy  | 3 (2.56 %)                  | 5 (1.31 %)                  | 0.009   |
| FPG (mmol/L)                   | 4.70 (4.30–5.00)            | 4.60 (4.20–5.00)            | 0.102   |
| 1hPG (mmol/L)                  | 10.00 (9.20–10.75)          | 9.80 (8.80–10.40)           | 0.007   |
| 2hPG (mmol/L)                  | 9.10 (8.55–9.80)            | 8.80 (8.40–9.40)            | 0.008   |
| TC (mmol/L)                    | 6.80 (5.90–7.70)            | 6.60 (5.70–7.40)            | 0.101   |
| TG (mmol/L)                    | 3.03 (2.14–3.83)            | 2.09 (1.73–2.58)            | < 0.001 |
| HDL-c (mmol/L)                 | 1.98 (1.46–2.32)            | 1.94 (1.74–2.17)            | 0.936   |
| LDL-c (mmol/L)                 | 4.11 (3.81–4.61)            | 3.31 (2.91–3.69)            | < 0.001 |
had previously experienced GDM. Furthermore, GDM women who progressed to early postpartum AGM, low insulin secretion, and low insulin sensitivity had higher mid-trimester TC and LDL-c concentrations.

The incidence of postpartum AGM in women with a history of GDM had been reported to vary between 2.6 and 38 % within 6–12 weeks of delivery [19, 20]. In the present study, the incidence of early postpartum AGM in women who had experienced GDM and had mid-trimester dyslipidemia was 56.41 %, which was significantly higher than the incidence in those with normal lipid concentrations (30.97 %). The serum concentrations of lipid parameters (TC, TG, LDL-c, and HDL-c) gradually increase from 12 weeks of pregnancy and show more marked increases during the second and third trimesters [21]. Numerous studies showed that serum lipid abnormalities were associated with disturbances in glucose metabolism [22, 23].

This study showed that GDM women with abnormal mid-trimester TG was predisposed to early postpartum AGM, which was consistent with the results of another retrospective study that was conducted in China [24]. A high TG was a lipid abnormality that commonly accompanies T2DM and prediabetic states [25]. Previous studies showed that the elevated TG concentration was an independent predictor of the development of diabetes in middle-aged women [26] and TG was a risk factor for postpartum glucose intolerance [27]. One potential link between TG and disturbances in glucose metabolism was that TG may induce insulin resistance. In the

Table 2 Comparisons of the early postpartum metabolic characteristics in women with GDM between mid-trimester dyslipidemia group and normal lipid group

| Variables                          | Dyslipidemia group (n = 117) | Normal lipid group (n = 381) | P value |
|------------------------------------|-----------------------------|-----------------------------|---------|
| Postpartum AGM                     | 66 (56.41 %)                | 118 (30.97 %)               | < 0.001 |
| Postpartum T2DM                    | 7 (5.98 %)                  | 9 (2.36 %)                  | < 0.001 |
| Postpartum IGT                     | 44 (37.61 %)                | 75 (19.69 %)                | < 0.001 |
| Postpartum IFG                     | 7 (5.98 %)                  | 20 (5.25 %)                 | 0.106   |
| Postpartum IGT + IFG               | 8 (6.84 %)                  | 14 (3.67 %)                 | < 0.001 |
| FPG (mmol/L)                       | 4.90 (4.40–5.40)            | 4.80 (4.30–5.40)            | 0.154   |
| 30 min PG (mmol/L)                 | 8.90 (8.30–9.70)            | 8.70 (8.20–9.50)            | 0.008   |
| 2hPG (mmol/L)                      | 7.30 (6.00–8.80)            | 7.10 (5.85–8.60)            | 0.012   |
| FINS (µU/mL)                       | 5.75 (3.84–9.01)            | 5.35 (3.65–8.27)            | 0.206   |
| 30 min INS(µU/mL)                  | 38.94 (28.43–59.58)         | 37.55 (26.77–59.41)         | 0.994   |
| 2 h INS(µU/mL)                     | 39.25 (21.23–65.12)         | 33.42 (21.65–52.58)         | 0.006   |
| IGI30                              | 7.55 (4.91–10.40)           | 11.35 (7.79–16.29)          | < 0.001 |
| ISI                                | 7.26 (5.21–11.56)           | 7.82 (5.25–13.27)           | 0.023   |
| DI                                 | 54.55 (32.73–84.34)         | 85.52 (57.42–122.61)        | < 0.001 |
| HOMA-β                             | 84.90 (62.30–127.91)        | 88.85 (61.91–135.66)        | 0.914   |
| HOMA-IR                            | 1.29 (0.79–2.03)            | 1.13 (0.75–1.77)            | 0.216   |
| TC (mmol/L)                        | 6.10 (5.60–7.20)            | 5.50 (4.80–6.10)            | 0.116   |
| TG (mmol/L)                        | 2.16 (1.74–2.61)            | 1.96 (1.65–2.58)            | 0.007   |
| HDL-c (mmol/L)                     | 1.86 (1.67–2.08)            | 1.81 (1.59–2.02)            | 0.943   |
| LDL-c (mmol/L)                     | 3.93 (3.33–4.60)            | 3.30 (2.83–3.78)            | < 0.001 |

Table 3 Logistic regression analysis of the relationships between the abnormal mid-trimester lipid parameters and early postpartum abnormal glucose metabolism

| Characteristicsa | Crude OR | 95 % CI | P value | Adjusted ORb | 95 % CI | P value |
|------------------|----------|---------|---------|--------------|---------|---------|
| Abnormal mid-trimester TC for postpartum AGM | 0.549    | 0.219–1.379 | 0.202 | 1.079 | 0.673–1.551 | 0.152 |
| Abnormal mid-trimester TG for postpartum AGM | 1.961    | 1.177–2.536 | 0.009 | 1.786 | 1.142–2.425 | 0.031 |
| Abnormal mid-trimester HDL-c for postpartum AGM | 0.397    | 0.174–0.903 | 0.321 | 1.080 | 0.814–1.317 | 0.267 |
| Abnormal mid-trimester LDL-c for postpartum AGM | 1.579    | 1.274–1.936 | 0.039 | 1.621 | 1.323–2.051 | 0.035 |

aThe reference values for all comparisons were those of the normal mid-trimester lipid parameters
bAdjustments were carried out for maternal age, family history of diabetes, insulin therapy and the three OGTT blood glucose values at 24–28 weeks of gestation, and the lipid parameters during early postpartum period
present study, we found that GDM women with postpartum AGM and low insulin sensitivity had high midtrimester TG concentrations. Free fatty acids (FFAs) derived from the high TG might mediate a vicious cycle between TG and insulin resistance [23, 28]. Excess FFAs concentrations might result in the generation of toxic lipid species, including diacylglycerides and ceramides. These toxic lipids contributed to endoplasmic reticulum stress, mitochondrial dysfunction, and the generation of reactive oxygen species, which together induced inflammation and insulin resistance [29, 30]. Furthermore, FFAs affected the fatty acid composition of cellular membranes, which directly affected cellular function, as well as the incorporation of insulin receptors into membranes [31]. Thus, the higher concentration of TG during pregnancy may have induced subsequent postpartum AGM mainly via FFAs.

Elevated plasma TC concentration was always recognized as an independent risk factor for metabolic syndrome, diabetes, and coronary heart disease [32]. Furthermore, a large retrospective study that showed that the TC concentration during early pregnancy was
an independent risk factor for GDM [33]. However, in the present study, mid-trimester TC was not significantly associated with postpartum AGM in women who had previously experienced GDM, whereas those with postpartum AGM, low insulin secretion, and low insulin sensitivity had high mid-trimester TC concentrations. This finding implied that the plasma TC concentration differed among women with distinct pathophysiologic subtypes of postpartum AGM, which may not be apparent when investigating AGM as a single group.

A previous study revealed that a high concentration of LDL-c in women with GDM was an independent risk factor for insulin resistance after delivery [34]. However, another study showed no significant difference in the LDL-c concentrations of postpartum women with NGT or AGM and a history of GDM [35]. The findings of this study were consistent with a positive association between LDL-c concentration and the prevalence of postpartum AGM. The underlying mechanisms of the associations between LDL-c and postpartum AGM were not fully understood. Some studies demonstrated that abnormal LDL-c metabolism might lead to the loss of function of pancreatic β-cells [36] and excessive LDL-c accumulation might aggravate oxidative stress, which correlated with insulin resistance [34, 37]. Consistent with this, the present study showed that GDM women with postpartum AGM, low insulin secretion, and low insulin sensitivity had elevated mid-trimester LDL-c concentrations. High LDL-c concentrations during the middle of pregnancy among GDM women were associated with both β-cell dysfunction and insulin resistance after delivery.

Oxidative stress [38] and chronic inflammation [39] are involved in the progression of GDM. There was a large body of research concerning the role of plasma HDL-c as a protective agent. HDL-c had anti-oxidant, anti-thrombotic, anti-inflammatory, vasodilatory effects, and a protective function against endothelial cell damage [40–42]. High concentrations of TG, TC, and LDL-c were common in pregnant women and especially associated with GDM [7, 33], whereas HDL-c did not change significantly during gestation even in GDM women [43]. This was similar to this study. In the present study, no significant differences were found in mid-trimester HDL-c concentrations between GDM women with postpartum AGM and those with NGT. Further investigation is needed to determine whether mid-trimester HDL-c is a protective factor for postpartum AGM.

Study strength and limitations
In the present study, the relationship between lipid profile during the mid-trimester and the pathophysiologic subtype of early postpartum abnormal glucose metabolism in women who experienced GDM was analyzed for the first time. This study also had several limitations. First, although the maternal lipid profile in the middle trimester (24–28 weeks of gestation) was assessed, the precise data of gestational weeks were not recorded. Lipid concentrations may change constantly through gestational weeks. Second, the body weight information of most GDM women before or during pregnancy was missing, limiting the possibility of analyzing the effect of overweight or obese on early postpartum AGM. Third, lipid profile may be closely associated with lifestyle. However, the information regarding the lifestyles of the participants was not collected, such as dietary factors and physical activity, which could be confounders. Finally, this was a hospital-based retrospective study and the sample lacked diversity. Therefore, further large multi-center studies with more rigorous design are needed in the future.

Conclusions
In conclusion, GDM women with abnormal mid-trimester TG and LDL-c concentrations were predisposed to early postpartum AGM. Postpartum AGM women who experienced GDM had heterogeneous mid-trimester lipid profile according to their pathophysiologic subtype. Among these postpartum AGM women, those with low insulin sensitivity had elevated mid-trimester TG concentrations, while those with low insulin secretion and low insulin sensitivity had higher mid-trimester TC and LDL-c concentrations. Thus, more attention should be paid to the mid-trimester lipid profile in women with GDM. For these women with abnormal lipid profile during midterm pregnancy, a low-fat diet, lifestyle modifications, and intensive follow-up are strongly recommended for the prevention of postpartum AGM.

Abbreviations
AGM: Abnormal glucose metabolism; CI: Confidence interval; DI: Disposition index; FFAs: Free fatty acids; FPG: Fasting plasma glucose; GDM: Gestational diabetes mellitus; HDL-c: High-density lipoprotein cholesterol; HOMA-β: Homeostasis model assessment of β-cell function; HOMA-ISI: Insulin sensitivity index; IGT: Impaired fasting glucose; IGI 30: 30-min insulinogenic index; IGT: Impaired glucose tolerance; IQR: Interquartile range; ISI: Insulin sensitivity index; LDL-c: Low-density lipoprotein cholesterol; NGT: Normal glucose tolerance; OGTT: Oral glucose tolerance test; OR: Odds ratio; TG: Triglyceride; TC: Total cholesterol; 1hPG: 1-h plasma glucose; 2hPG: 2-h plasma glucose

Acknowledgements
We thank Mark Cleasby, PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the English text of a draft of the manuscript.

Authors’ contributions
Xiaopei Cao conceived and designed the study. Fenghua Lai and Zeting Li did the data analysis, interpreted the data and wrote the draft manuscript. Ling Pei, Shufan Yue, Huangmeng Xiao, and Zhuyu Li collected the data. Yanbing Li and Haipeng Xiao performed critical revision on the manuscript. All authors approved the final version before submission.
Funding
This work was supported by the grants from the National major and development projects of China (Grant number: 2018YFC1314100), the Science and Technology Foundation of Guangzhou City (Grant number: 201803010101), and the Clinical Medical 5010 Project Foundation of Sun Yat-sen University (Grant number: 2017001).

Availability of data and materials
All data used in this study are available from the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Research Ethics Committee of the First Affiliated Hospital, Sun Yat-sen University (No. 2020048). For this type of study, involving analysis of deidentified participant data, formal consent was waived.

Consent for publication
All authors provide consent for publication of this paper.

Competing interests
The authors have no conflict of interest to declare.

Author details
1Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Rd, 510080 Guangzhou, China. 2Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, 510080 Guangzhou, China.

Received: 25 May 2021 Accepted: 10 August 2021
Published online: 24 August 2021

References
1. Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002. https://doi.org/10.1056/NEJMoa0707943.
2. Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95:2734–46. https://doi.org/10.1016/j.mayocp.2020.02.019.
3. Kim C, Berger DK, Channay S. Recurrence of gestational diabetes mellitus: a systematic review. Diabetes Care. 2007;30:1314–9. https://doi.org/10.2337/dc07-0651.
4. Vounzoulaki E, Khunti K, Abner SC, Tan BK, Davies MJ, Gillies CL. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ. 2020;369:1361. https://doi.org/10.1136/bmj.l361.
5. American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2020. Diabetes Care. 2020;43:183–92. https://doi.org/10.2337/doi-120-5014.
6. Jones EJ, Hernandez TL, Edmonds JK, Ferranti EP. Continued Disparities in Postpartum Follow-Up and Screening Among Women With Gestational Diabetes and Hypertensive Disorders of Pregnancy: A Systematic Review. J Perinat Neonatal Nurs. 2019;33:136–48. https://doi.org/10.1097/JPN.0000000000001399.
7. Chafer-Graf UM, Graf K, Kulbacka I, Kjos SL, Duddenhausen J, Vetter K, et al. Maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum? Am J Obstet Gynecol. 2019;221:150.e1–13. https://doi.org/10.1016/j.ajog.2019.03.025.
8. Adark MC, Benschip L, Peterbroers KR, Smak GA, Kors AW, Mulder MT, et al. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum? Am J Obstet Gynecol. 2019;221:150.e1–13. https://doi.org/10.1016/j.ajog.2019.03.025.
9. Jin WY, Lin SL, Hou RL, Chen XY, Han T, JIN Y, et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China. BMC Pregnancy Childbirth. 2016;16:60. https://doi.org/10.1186/s12884-016-0852-9.
10. Layton J, Powe C, Allard C, Battista MC, Doyon M, Bouchard L, et al. Maternal lipid profile differs by gestational diabetes physiologic subtype. Metabolism. 2019;91:39–42. https://doi.org/10.1016/j.metabol.2018.11.008.
11. Tura A, Kautzky-Willer A, Pacini G. Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. Diabetes Res Clin Pract. 2006;72:298–301. https://doi.org/10.1016/j.diabres.2005.10.005.
12. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9. https://doi.org/10.1007/BF00280863.
13. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing; comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70. https://doi.org/10.2337/diacare.22.9.1462.
14. Utschneider KM, Prigeon RL, Faivre M, Voutilainen M, Jovanovic A, Treacher DF, et al. Elevated maternal triglyceride levels during pregnancy are associated with beta-cell function. Diabetes Care. 2007;30:335–41. https://doi.org/10.2337/dc06-1478.
15. Metzger BE, Gabbe SG, Persson B, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33:3676–82. https://doi.org/10.2337/dc09-1848.
16. Wang C, Kong L, Yang Y, Wei Y, Zhu W, Su R, et al. Recurrence reference values for serum lipids during early and middle pregnancy: a retrospective study from China. Lipids Health Dis. 2018;17:246. https://doi.org/10.1186/s12944-018-0885-3.
17. Weng J. Evolution in the Chinese Diabetes Society Standards of Care for Type 2 Diabetes. Diabetes Metab Res Rev. 2016;32:440–1. https://doi.org/10.1111/dmr.12826.
18. Onn JH, Kwak SH, Cho YM, Lim S, Jang HC, Park KS, et al. 10-year trajectory of beta-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabetes Endocrinol. 2016;4:27–34. https://doi.org/10.1016/S2213-8587(15)00336-8.
19. Ogonoowski J, Miazgowcki T. The prevalence of 6 weeks postpartum abnormal glucose tolerance in Caucasian women with gestational diabetes. Diabetes Res Clin Pract. 2009;84:239–44. https://doi.org/10.1016/j.diabres.2009.04.003.
20. Ghajari H, Nouhijaj S, Shahbazian H, Valizadeh R, Tahery N, Postpartum I. The prevalence of abnormal glucose tolerance in Caucasian women with gestational diabetes. Diabetes Care. 2008;31:213–9. https://doi.org/10.2337/dc07-1181.
21. Bartels A, Egan N, Broadhurst DI, Khashan AS, Joyce C, Stapleton M, et al. Maternal serum cholesterol levels are elevated from the 1st trimester of pregnancy: a cross-sectional study. J Obstet Gynaecol. 2012;32:747–52. https://doi.org/10.3109/01443615.2012.714017.
22. Herrero E, Ortega-Senovilla H. Disturbances in Lipid metabolism in diabetic pregnancy - Are these the cause of the problem? Best Pract Res Clin Endocrinol. 2011;25:455–6. https://doi.org/10.1016/j.beem.2011.05.006.
23. Lasram MM, Bouzid K, Douib IB, Annabi A, El FS, et al. Lipid metabolism disturbances contribute to insulin resistance and decrease insulin sensitivity by malathion exposure in Wistar rat. Drug Chem Toxicol. 2015;38:227–34. https://doi.org/10.1177/0148054514533434.
24. Lai M, Fang F, Ma Y, Yang J, Huang J, Li N, et al. Elevated Midtrimester Triglycerides as a Biomarker for Postpartum Hyperglycemia in Gestational Diabetes. J Diabetes Res. 2020;2020:3950652. https://doi.org/10.1155/2020/3950652.
25. Ginsberg NN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005;36:232–40. https://doi.org/10.1016/j.arcmed.2005.01.005.
26. Dotseva A, Johansson S, Wilhelmsen L, Rosengren A. Increased levels of triglycerides, BMI and blood pressure and low physical activity increase the risk of diabetes in Swedish women. A prospective 18-year follow-up of the BEDA study. Diabet Med. 2004;21:615–22. https://doi.org/10.1111/j.1464-5491.2004.01895.x.
27. Lai M, Kim MY, Yang JH, Park SY, Yim CH, Han KO, et al. Nutritional risk factors of early development of postpartum prediabetes and diabetes in women with gestational diabetes mellitus. Nutrition. 2011;27:782–8. https://doi.org/10.1016/j.nut.2010.08.019.
28. Kristoffen A, Velagapudi VR, Yetukuri L, Westerbacka J, Bergholm R, Ekroos K, et al. Serum saturated fatty acids containing tricylglycerol are better

Page 8 of 9

Lai et al. Lipids in Health and Disease (2021) 20:91
markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia. 2009;52:684–90. https://doi.org/10.1007/s00125-009-1282-2.

29. Sears B, Perry M. The role of fatty acids in insulin resistance. Lipids Health Dis. 2015;14:121. https://doi.org/10.1186/s12944-015-0123-1.

30. Oh YS, Bae GD, Baek DJ, Park EY, Jun HS. Fatty acid-induced lipotoxicity in pancreatic beta-cells during development of type 2 diabetes. Front Endocrinol (Lausanne). 2018;9:384. https://doi.org/10.3389/fendo.2018.00384.

31. Pilon M. Revisiting the membrane-centric view of diabetes. Lipids Health Dis. 2016;15:167. https://doi.org/10.1186/s12944-016-0342-0.

32. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. Atherosclerosis. 2016;248:123–31. https://doi.org/10.1016/j.atherosclerosis.2016.03.016.

33. Wang C, Zhu W, Wei Y, Su R, Feng H, Hadar E, et al. The associations between early pregnancy lipid profiles and pregnancy outcomes. J Perinatol. 2017;37:127–33. https://doi.org/10.1038/jp.2016.191.

34. Ma Y, Wang N, Gu L, Wei X, Ren Q, Huang Q, et al. Postpartum assessment of the beta cell function and insulin resistance for Chinese women with previous gestational diabetes mellitus. Gynecol Endocrinol. 2019;35:174–8. https://doi.org/10.1080/09513590.2018.1512094.

35. Prados M, Flores-Le RJ, Benaiges D, Llarado G, Chollaron JJ, Paya A, et al. Previous Gestational Diabetes Increases Atherogenic Dyslipidemia in Subsequent Pregnancy and Postpartum. Lipids. 2018;53:387–92. https://doi.org/10.1002/lipd.12040.

36. Abderrahmane A, Niederhauser G, Favre D, Abdelli S, Feraudoussi M, Yang JY, et al. Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia. 2007;50:1304–14. https://doi.org/10.1007/s00125-007-0642-z.

37. Li W, Zhang S, Liu H, Wang L, Zhang C, Leng J, et al. Different associations of diabetes with beta-cell dysfunction and insulin resistance among obese and nonobese Chinese women with prior gestational diabetes mellitus. Diabetes Care. 2014;37:2533–9. https://doi.org/10.2337/dc14-0573.

38. Lappas M, Permezel M, Rice GE. Release of proinflammatory cytokines and 8-isoprostane from placenta, adipose tissue, and skeletal muscle from normal pregnant women and women with gestational diabetes mellitus. J Clin Endocrinol Metab. 2004;89:5627–33. https://doi.org/10.1210/jc.2003-032097.

39. Mrizak I, Arfa A, Fekhi M, Debbabi H, Bouslema A, Boumaiza I, et al. Inflammation and impaired endothelium-dependant vasodilatation in non obese women with gestational diabetes mellitus: preliminary results. Lipids Health Dis. 2013;12:93. https://doi.org/10.1186/1476-511X-12-93.

40. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck LK, Baba HA, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113:569–81. https://doi.org/10.1172/JCI18004.

41. Sakuma N, Yoshikawa M, Hibiyo T, OhTe N, Kamiya T, Kunimatsu M, et al. HDL3 exerts a more powerful antiperoxidative and protective effect against peroxidative modification of LDL than HDL2 does. J Nutr Sci Vitaminol (Tokyo). 2002;48:278–82. https://doi.org/10.3177/jnsv.48.278.

42. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol. 2008;23:370–8. https://doi.org/10.1097/HCO.0b013e3283043806.

43. Wiznitzer A, Mayer A, Novack V, Sheiner E, Gilutz H, Malhotra A, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol. 2009;201:481–2. https://doi.org/10.1016/j.ajog.2009.05.032.